Joline J. Lim

1E Lower Kent Ridge Road
Singapore, 119228, Singapore

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Journal: The New England journal of medicine

Published: December 10, 2025

Cancer type and gene signatures associated with breakthrough infections following COVID-19 mRNA vaccination.

Cancer type and gene signatures associated with breakthrough infections following COVID-19 mRNA vaccination.

Journal: NPJ vaccines

Published: November 18, 2024

NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies.

NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies.

Journal: Therapeutic advances in medical oncology

Published: November 07, 2024

Safety and feasibility of concomitant scalp cooling and limb cryocompression to prevent paclitaxel-induced alopecia and neuropathy.

Safety and feasibility of concomitant scalp cooling and limb cryocompression to prevent paclitaxel-induced alopecia and neuropathy.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: March 27, 2024

First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.

First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.

Journal: EBioMedicine

Published: March 01, 2024

Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit.

Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit.

Journal: Frontiers in oncology

Published: November 21, 2023

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2- Metastatic Breast Cancer.

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2- Metastatic Breast Cancer.

Journal: Cancers

Published: August 09, 2023

Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines.

Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 21, 2023

A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.

A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.

Journal: Targeted oncology

Published: March 24, 2023

Immune checkpoint inhibitor combinations-current and emerging strategies.

Immune checkpoint inhibitor combinations-current and emerging strategies.

Journal: British journal of cancer

Published: January 06, 2023

Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials.

Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials.

Journal: British journal of cancer

Published: July 23, 2022

Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia.

Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia.

Journal: Therapeutic advances in medical oncology

Published: July 12, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026